BE2016C056I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C056I2
BE2016C056I2 BE2016C056C BE2016C056C BE2016C056I2 BE 2016C056 I2 BE2016C056 I2 BE 2016C056I2 BE 2016C056 C BE2016C056 C BE 2016C056C BE 2016C056 C BE2016C056 C BE 2016C056C BE 2016C056 I2 BE2016C056 I2 BE 2016C056I2
Authority
BE
Belgium
Prior art keywords
antagonists
subject
present disclosure
disclosure
neutralize
Prior art date
Application number
BE2016C056C
Other languages
French (fr)
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of BE2016C056I2 publication Critical patent/BE2016C056I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Luminescent Compositions (AREA)
  • Glass Compositions (AREA)

Abstract

The present disclosure is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The disclosure also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present disclosure also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists.
BE2016C056C 2003-05-08 2016-10-24 BE2016C056I2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46921103P 2003-05-08 2003-05-08
US55762104P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
EP04760993A EP1624892B1 (en) 2003-05-08 2004-05-10 Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
BE2016C056I2 true BE2016C056I2 (en) 2023-08-09

Family

ID=33459144

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C056C BE2016C056I2 (en) 2003-05-08 2016-10-24

Country Status (25)

Country Link
US (8) US20050025763A1 (en)
EP (4) EP2371391B1 (en)
JP (4) JP4887152B2 (en)
KR (1) KR101268707B1 (en)
CN (1) CN1805755B (en)
AT (1) ATE506076T1 (en)
AU (2) AU2004238363B2 (en)
BE (1) BE2016C056I2 (en)
BR (1) BRPI0410129B8 (en)
CA (1) CA2523001C (en)
CY (4) CY1111958T1 (en)
DE (1) DE602004032328D1 (en)
DK (3) DK1624892T3 (en)
ES (2) ES2643289T3 (en)
FR (1) FR16C1012I2 (en)
HK (1) HK1208815A1 (en)
HU (2) HUE034908T2 (en)
LT (1) LT2853272T (en)
LU (1) LU93274I2 (en)
MX (1) MXPA05012011A (en)
NL (1) NL300838I2 (en)
PL (3) PL2853272T3 (en)
PT (3) PT2853272T (en)
SI (3) SI2371391T1 (en)
WO (1) WO2004100898A2 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
AU2007281684C1 (en) * 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
AU2007281682B2 (en) * 2006-08-07 2013-05-16 Abbvie Biotherapeutics Inc. Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
WO2008019379A2 (en) * 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
CA2726804C (en) 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
JP2012507555A (en) * 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション Use of anti-CS1 antibodies in the treatment of rare diseases
JP5818688B2 (en) * 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド Methods and compositions for improving the efficiency of nucleic acid amplification reactions
US20120269814A1 (en) * 2009-11-10 2012-10-25 Amgen Inc. Anti-c mpl antibodies
CA2787070A1 (en) * 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
CN105777907B (en) 2010-02-24 2020-03-17 伊缪诺金公司 Folate receptor 1 antibodies and immunoconjugates and uses thereof
ES2661466T3 (en) 2011-04-01 2018-04-02 Immunogen, Inc. Methods to increase the effectiveness of cancer therapy with FOLR1
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
JP6374392B2 (en) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド XBP1, CD138 and CS1 peptides, pharmaceutical compositions containing the peptides, and methods of using such peptides and compositions
AU2014233478A1 (en) * 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
ES2699599T3 (en) * 2013-03-15 2019-02-11 Abbvie Biotherapeutics Inc Fc variants
DK2992020T3 (en) * 2013-05-03 2020-02-10 Ohio State Innovation Foundation CS1-SPECIFIC CHEMICAL ANTIGEN RECEPTOR-MANIPULATED IMMUNE EFFECT CELLS
US20160159918A1 (en) * 2013-07-24 2016-06-09 The General Hospital Corporation Methods for diagnosing and treating immune disease
NZ717140A (en) 2013-08-30 2022-05-27 Immunogen Inc Antibodies and assays for detection of folate receptor 1
WO2015057674A1 (en) 2013-10-14 2015-04-23 Club Car, Llc Self-preloading shift lever
EP3066128B1 (en) 2013-11-06 2018-10-31 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
ES2779412T3 (en) * 2014-06-17 2020-08-17 Medimmune Ltd Enhanced Alpha-V Beta-8 Antibodies
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
US10752902B2 (en) * 2014-09-23 2020-08-25 Board Of Trustees Of Michigan State University Compositions comprising fusion proteins useful for modulating an immune response
CA2966005C (en) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
AU2015358462A1 (en) 2014-12-04 2017-07-27 Bristol-Myers Squibb Company Combination of anti-CS1 and anti-PD1 antibodies to treat cancer (myeloma)
DE102015102183B4 (en) * 2015-02-16 2018-03-01 Robert Bosch Automotive Steering Gmbh Steering intermediate shaft for a motor vehicle and method for operating a steering intermediate shaft for a motor vehicle
CN107530424A (en) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 For NKG2D and the bivalent antibody of tumor associated antigen
WO2016168766A1 (en) * 2015-04-15 2016-10-20 The California Institute For Biomedical Research Optimized chimeric receptor t cell switches and uses thereof
DK3313528T3 (en) 2015-06-29 2021-09-20 Bristol Myers Squibb Co IMMUNTERAPEUTIC DOSAGE SCHEMES INCLUDING POMALIDOMID AND AN ANTI-CS1 ANTIBODY FOR THE CANCER OF CANCER
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
CN122075735A (en) 2015-09-17 2026-05-26 伊缪诺金公司 Treatment combinations containing anti-FOLR1 immunoconjugates
PT3370768T (en) * 2015-11-03 2022-04-21 Janssen Biotech Inc ANTIBODIES THAT SPECIFICALLY BIND TO PD-1 AND THEIR USES
IL269318B2 (en) * 2017-03-13 2024-10-01 Intrinsic Lifesciences Llc Antibodies to human erythroferrone and uses thereof
US11124579B2 (en) 2017-03-29 2021-09-21 Agency For Science, Technology And Research Anti oligosaccharide antibody
CN110997902B (en) 2017-06-20 2021-11-30 居里研究所 SUV39H1 deficient immune cells
KR20230008269A (en) 2017-08-07 2023-01-13 엔비이-테라퓨틱스 아게 Antibody drug conjugates having high in vivo tolerability
MA49911A (en) 2017-11-01 2020-06-24 Juno Therapeutics Inc ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN
JP7357626B2 (en) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド Process for producing therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
BR112020011223A2 (en) 2017-12-08 2020-11-17 Juno Therapeutics Inc phenotypic markers for cell therapy and related methods
CN119193493A (en) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 Process for producing engineered T cell compositions
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
TW201946654A (en) 2018-03-05 2019-12-16 比利時商健生藥品公司 Anti-PHF-Tau antibodies and uses thereof
US11629179B2 (en) 2018-06-29 2023-04-18 Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
CN112805378A (en) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 Methods for assessing integrated nucleic acids
CN109406798A (en) * 2018-10-29 2019-03-01 美康生物科技股份有限公司 Creatinine enzyme process detection kit
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN119569895A (en) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G protein coupled receptor class C group 5 member D (GPRC 5D) specific chimeric antigen receptor
IL263394A (en) * 2018-11-29 2020-05-31 Amit Ido Methods for activating inactive immune cells and cancer treatment
CA3136737A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
EP4003407A1 (en) 2019-07-23 2022-06-01 Mnemo Therapeutics Immune cells defective for suv39h1
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof
WO2021158660A2 (en) * 2020-02-05 2021-08-12 Navaux, Inc. Anti-hepsin antibodies and uses thereof
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
KR20230024283A (en) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 Methods for identifying features associated with clinical response and uses thereof
EP4171616A1 (en) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
JP7886313B2 (en) 2020-07-30 2026-07-07 アンスティテュ・クリー Immune cells with a defect in SOCS1
CN114286691B (en) * 2020-08-06 2024-08-06 武汉思安医疗技术有限公司 CS1-antibodies and anti-CS1-CAR-T cells
JP2023549780A (en) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド Cells expressing chimeric receptors from engineered invariant CD3 immunoglobulin superfamily chain loci and related polynucleotides and methods
KR20230165771A (en) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 Combination of T cell therapy and DGK inhibitor
CN117916256A (en) 2021-05-06 2024-04-19 朱诺治疗学有限公司 Methods for stimulating and transducing T cells
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
US20250304915A1 (en) 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
JP2025501272A (en) 2021-12-28 2025-01-17 ムネモ・セラピューティクス Immune cells with inactivated SUV39H1 and modified TCR
KR20240137075A (en) 2022-01-28 2024-09-19 주노 쎄러퓨티크스 인코퍼레이티드 Method for preparing a cell composition
CA3252736A1 (en) 2022-02-18 2023-08-24 Rakuten Medical, Inc. Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
EP4499677A1 (en) 2022-03-31 2025-02-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
CN115141825A (en) * 2022-08-12 2022-10-04 武汉希望组生物科技有限公司 Extraction method of micro insect genome DNA
KR20250061756A (en) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 Combination of T cell therapy and continuous or intermittent DGK inhibitor administration
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
EP4626924A4 (en) * 2022-12-02 2026-07-15 Guangzhou Litai Biotechnology Co Ltd HUMAN CS1 CAR T CELLS
CN121100267A (en) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 Machine learning method for predicting cell phenotype using holographic imaging
US20260232729A1 (en) 2023-02-03 2026-08-13 C3S2 Gmbh Methods for non-viral manufacturing of engineered immune cells
US20260001951A1 (en) 2024-06-28 2026-01-01 Immunitybio, Inc. Anti-SLAMF7 Antibodies And Therapeutics
WO2026093520A1 (en) 2024-10-31 2026-05-07 Institut Curie Short-csf1-associated extracellular vesicles and uses thereof
WO2026133125A1 (en) 2024-12-16 2026-06-25 Janssen Biotech, Inc. T cell-specific promoters and methods of use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5004692A (en) 1987-12-15 1991-04-02 Protein Design Labs, Inc. Cloning and expression of phosopholipase C genes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
KR0162259B1 (en) 1989-12-05 1998-12-01 아미 펙터 Chimeric Antibodies for Detection and Treatment of Infectious and Inflammatory Lesions
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JPH07503132A (en) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド Transgenic non-human animals capable of producing xenoantibodies
US5644048A (en) 1992-01-10 1997-07-01 Isis Pharmaceuticals, Inc. Process for preparing phosphorothioate oligonucleotides
JPH07101999A (en) * 1993-10-06 1995-04-18 Hagiwara Yoshihide Amino acid sequence of anti-idiotype antibody against anti-cancer human monoclonal antibody and DNA base sequence encoding the same
US5637684A (en) 1994-02-23 1997-06-10 Isis Pharmaceuticals, Inc. Phosphoramidate and phosphorothioamidate oligomeric compounds
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
WO1996039518A1 (en) 1995-06-05 1996-12-12 Bionebraska, Inc. Lead binding polypeptides and nucleotides coding therefor
US6607898B1 (en) * 1996-03-26 2003-08-19 Oncomedx, Inc. Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum
WO1998042738A1 (en) 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
IL139686A0 (en) 1998-06-02 2002-02-10 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU6020599A (en) 1998-08-25 2000-03-14 Incyte Pharmaceuticals, Inc. Cell surface immunomodulators
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2757500A (en) 1999-02-10 2000-08-29 Human Genome Sciences, Inc. 33 human secreted proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
WO2000055627A1 (en) 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Reusable low fluorescent plastic biochip
JP2004522402A (en) 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1208202A2 (en) 1999-09-01 2002-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001046260A2 (en) * 1999-12-23 2001-06-28 Bristol-Myers Squibb Company Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof
AU6802801A (en) 2000-03-01 2001-09-24 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1266014A2 (en) * 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
AU2001266604A1 (en) 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US6410271B1 (en) 2000-06-23 2002-06-25 Genetastix Corporation Generation of highly diverse library of expression vectors via homologous recombination in yeast
BR0206985A (en) * 2001-01-29 2005-04-19 Idec Pharma Corp Modified Antibodies and Methods of Use
EP1423134A2 (en) 2001-03-21 2004-06-02 Human Genome Sciences Human secreted proteins
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002313559A1 (en) 2001-08-23 2003-03-10 Oxford Biomedica (Uk) Limited Genes
US20040038877A1 (en) 2001-10-02 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6478825B1 (en) * 2001-11-28 2002-11-12 Osteotech, Inc. Implant, method of making same and use of the implant for the treatment of bone defects
US7041499B2 (en) * 2001-12-12 2006-05-09 University Of North Texas Health Science Center Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth
CA2832136C (en) 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
JP2012507555A (en) 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション Use of anti-CS1 antibodies in the treatment of rare diseases
US9701019B2 (en) 2011-09-15 2017-07-11 Convergent Information Technologies Gmbh System and method for the automatic generation of robot programs
ES2741897T3 (en) 2012-02-13 2020-02-12 Radius Eng Inc Reusable cartridge for injection molding

Also Published As

Publication number Publication date
US20160002335A1 (en) 2016-01-07
WO2004100898A2 (en) 2004-11-25
SI2371391T1 (en) 2014-12-31
CY1119353T1 (en) 2018-02-14
CN1805755A (en) 2006-07-19
EP2853272B1 (en) 2017-08-02
JP5976288B2 (en) 2016-08-23
PL2853272T3 (en) 2018-01-31
JP6042834B2 (en) 2016-12-14
US10442859B2 (en) 2019-10-15
DK2371391T3 (en) 2014-11-03
CA2523001C (en) 2013-12-31
MXPA05012011A (en) 2006-02-03
EP2371391A1 (en) 2011-10-05
SI2853272T1 (en) 2017-10-30
DK1624892T3 (en) 2011-08-08
JP2007503465A (en) 2007-02-22
EP1624892B1 (en) 2011-04-20
US20090238827A1 (en) 2009-09-24
US20120064083A1 (en) 2012-03-15
BRPI0410129A (en) 2006-05-16
HUE034908T2 (en) 2018-03-28
CY2016035I2 (en) 2017-09-13
DE602004032328D1 (en) 2011-06-01
EP1624892A2 (en) 2006-02-15
AU2010214661B2 (en) 2012-05-17
ES2516840T3 (en) 2014-10-31
LU93274I2 (en) 2016-12-27
ATE506076T1 (en) 2011-05-15
JP2012121878A (en) 2012-06-28
US20050025763A1 (en) 2005-02-03
WO2004100898A3 (en) 2005-08-18
BRPI0410129B1 (en) 2020-02-11
KR101268707B1 (en) 2013-05-29
EP3275463A1 (en) 2018-01-31
US8133981B2 (en) 2012-03-13
CY1111958T1 (en) 2015-11-04
US20100168397A1 (en) 2010-07-01
CA2523001A1 (en) 2004-11-25
HK1163497A1 (en) 2012-09-14
US8445646B2 (en) 2013-05-21
HK1089374A1 (en) 2006-12-01
EP1624892A4 (en) 2007-08-08
NL300838I2 (en) 2017-01-03
BRPI0410129B8 (en) 2021-05-25
US9175081B2 (en) 2015-11-03
US8008450B2 (en) 2011-08-30
ES2643289T3 (en) 2017-11-22
PL2371391T3 (en) 2015-01-30
CY1115671T1 (en) 2017-01-25
US20140065063A1 (en) 2014-03-06
KR20060018837A (en) 2006-03-02
PT2853272T (en) 2017-08-30
JP2017019795A (en) 2017-01-26
CY2016035I1 (en) 2017-09-13
AU2004238363B2 (en) 2010-05-27
HUS1600042I1 (en) 2016-11-28
PT1624892E (en) 2011-07-12
HK1208815A1 (en) 2016-03-18
EP2853272A1 (en) 2015-04-01
LT2853272T (en) 2017-10-10
FR16C1012I2 (en) 2019-01-11
AU2004238363A1 (en) 2004-11-25
PL1624892T3 (en) 2011-09-30
PT2371391E (en) 2014-10-30
EP2371391B1 (en) 2014-07-23
JP4887152B2 (en) 2012-02-29
DK2853272T3 (en) 2017-11-06
SI1624892T1 (en) 2011-08-31
JP2014139187A (en) 2014-07-31
AU2010214661A1 (en) 2010-09-16
CN1805755B (en) 2011-06-01
US20090238835A1 (en) 2009-09-24
US20200031929A1 (en) 2020-01-30
FR16C1012I1 (en) 2016-09-12

Similar Documents

Publication Publication Date Title
NL300838I2 (en)
DE602004029399D1 (en)
BRPI0413489A (en) cd20 binding polypeptide compositions
MXPA06003788A (en) Fully human antibodies against human 4-1bb (cd137).
EA200100822A1 (en) BAFF, RELATED TO IT BLOCKING AGENTS AND THEIR APPLICATION IN STIMULATION AND INHIBITION OF B-CELLS AND IMMUNOGLOBULINS IN IMMUNE REACTIONS
UA89350C2 (en) Humanized antibody that specifically binds human cd20
DK1265928T3 (en) RSV neutralizing antibodies with ultra high affinity
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
AU6842701A (en) Antibodies that immunospecifically bind to blys
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
CY1115003T1 (en) THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
WO2005014653A3 (en) Humanized chicken antibodies
WO2001090361A3 (en) Modulation of inflammation by protease-treated mcp-3 chemokine
UA91182C2 (en) Antibody that specifically binds to connective tissue growth factor (ctgf)